Fig. 5: Superior antitumor effect of PD-1Ab21 treatment. | Nature Communications

Fig. 5: Superior antitumor effect of PD-1Ab21 treatment.

From: Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Fig. 5: Superior antitumor effect of PD-1Ab21 treatment.

a Balb/c mice transplanted s.c. with CT26 cells (left) or C57BL/6 mice transplanted s.c. with MC38 cells (right) were treated with anti-PD-1, PD-1Ab + IL-21, or PD-1Ab21 (n = 5 mice /group). b Balb/c mice (n = 5 mice /group) transplanted s.c. with TUBO cells were treated with anti-Her2/neu antibody alone or in combination with PD-1Ab + IL-21 or PD-1Ab21. c C57BL/6 mice (n = 5 mice /group) transferred with 1 × 106 naïve CD90.1+ OT-1 cells 1 d before inoculation of B16-OVA cells were immunized with poly I:C and OVA257-264 peptide, followed by treatment with anti-PD-1, PD-1Ab + IL-21, or PD-1Ab21. Tumor length (a) and width (b) were measured and tumor volume was calculated as (ab2/2). Tumor growth is shown as mean tumor size ±SEM over time. Results were compared using two-way ANOVA followed by Tukey’s multiple comparison test. a CT26: *p = 0.0167, **p = 0.0024, ****p < 0.0001; MC38: *p = 0.0445 (anti-PD-1 vs. PD-1Ab21), *p = 0.0242 (PD-1Ab+IL-21 vs. PD-1Ab21). b *p = 0.0223 (anti-neu vs. anti-neu+PD-1Ab+IL-21), *p = 0.0335 (anti-neu+PD-1Ab+IL-21 vs. anti-neu+ PD-1Ab21), ****p < 0.0001. c **p = 0.0015, ****p < 0.0001, n.s. not significant. One representative experiment out of three independent experiments is shown.

Back to article page